Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7594770rdf:typepubmed:Citationlld:pubmed
pubmed-article:7594770lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0036536lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0036537lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0030298lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0030274lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0037659lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0017687lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:7594770lifeskim:mentionsumls-concept:C1549542lld:lifeskim
pubmed-article:7594770pubmed:issue1lld:pubmed
pubmed-article:7594770pubmed:dateCreated1995-12-13lld:pubmed
pubmed-article:7594770pubmed:abstractTextThe current study was undertaken to determine whether intraislet somatostatin regulates glucagon or pancreatic polypeptide (PP) secretion in the human pancreas. A high-affinity, high-specificity monoclonal somatostatin antibody (CURE.S6) was used to immunoneutralize somatostatin in the isolated, perfused human pancreas. Single-pass perfusion was performed in pancreata obtained from cadaveric organ donors using a modified Krebs media with either 3.9 or 12.9 mM glucose. Sequential test periods separated by basal periods were performed with infusion of either exogenous somatostatin-14 (SS-14), CURE.S6, or a combined infusion. Infusion of SS-14 did not significantly alter glucagon or PP secretion during low-glucose or high-glucose perfusion. Immunoneutralization of intraislet somatostatin with CURE.S6 resulted in a significant increase of glucagon secretion under low-glucose conditions (delta X = 15 +/- 3 pM) (p < 0.05), but did not significantly effect glucagon secretion under high-glucose conditions (delta X = -2 +/- 3 pM) (p = NS). PP secretion remained unchanged during CURE.S6 infusion. Combined infusion of SS-14 and CURE.S6 did not significantly alter glucagon or PP secretion. The data suggest that intraislet somatostatin may have an inhibitory role in the regulation of glucagon secretion during low-glucose conditions and that intraislet somatostatin does not regulate PP secretion in the isolated, perfused human pancreas.lld:pubmed
pubmed-article:7594770pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7594770pubmed:languageenglld:pubmed
pubmed-article:7594770pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7594770pubmed:citationSubsetIMlld:pubmed
pubmed-article:7594770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7594770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7594770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7594770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7594770pubmed:statusMEDLINElld:pubmed
pubmed-article:7594770pubmed:monthAuglld:pubmed
pubmed-article:7594770pubmed:issn0169-4197lld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:WalshJJlld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:KleinmanRRlld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:WongHHlld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:GingerichRRlld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:OhningGGlld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:BrunicardiF...lld:pubmed
pubmed-article:7594770pubmed:authorpubmed-author:OlthoffKKlld:pubmed
pubmed-article:7594770pubmed:issnTypePrintlld:pubmed
pubmed-article:7594770pubmed:volume18lld:pubmed
pubmed-article:7594770pubmed:ownerNLMlld:pubmed
pubmed-article:7594770pubmed:authorsCompleteYlld:pubmed
pubmed-article:7594770pubmed:pagination51-7lld:pubmed
pubmed-article:7594770pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:meshHeadingpubmed-meshheading:7594770-...lld:pubmed
pubmed-article:7594770pubmed:year1995lld:pubmed
pubmed-article:7594770pubmed:articleTitleThe influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas.lld:pubmed
pubmed-article:7594770pubmed:affiliationDepartment of Surgery, VAMC-West Los Angeles, CA, USA.lld:pubmed
pubmed-article:7594770pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7594770pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7594770pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:7594770pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7594770lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7594770lld:pubmed